Drug science with real-world consequences.
Pharmacology News pairs plainspoken questions with long, specialist answers about how drugs, treatments, and health systems affect real lives. Its conversations range from serotonin and depression to ibogaine, vitamin D, steroids, homelessness, and recovery.
PRESS PLAY
Pharmacology News is a brisk, interview-centered show about drugs in the broadest sense: psychiatric medications, illegal substances, supplements, psychedelics, hormones, and the policies that decide how people encounter them. It does not stay in the lab. The conversations regularly move from receptor systems and study design into homelessness, addiction recovery, clinical practice, public health, and the ordinary consequences of medical claims. Dr. Carlos tends to ask plainly. Guests often answer at length. That structure gives the show a talk-radio texture, with enough technical vocabulary to satisfy science-minded listeners and enough everyday framing to keep the stakes visible. Episodes on Dr. Joanna Moncrief's Chemically Imbalanced examine the serotonin myth, antidepressant studies, placebo comparisons, adverse effects, and the ways research outcomes can be presented to look stronger than they are. Discussions with Dr. Stacey B. Armstrong turn toward ibogaine, psychedelics, pharmacokinetics, neuroplasticity, and why a drug that may affect reward circuits remains difficult to explain cleanly. Dr. Gominak's episode widens the pharmacology frame to vitamin D, UVB light, sleep, rickets, teeth, and the biological cost of living indoors. Dr. Randolph Nessie's evolutionary psychiatry conversations ask why natural selection left humans with fragile minds and why emotions such as panic, grief, or low mood might have functions as well as costs. Dr. Harrison G. Pope brings anabolic steroids into the mix, including their history, prevalence, and reputation. The Tom Wolf episodes are more personal and more political. They connect heroin and fentanyl addiction, homelessness, recovery work, veterans, supportive housing, and the limits of services that sound stronger on paper than they may be in practice. Across these topics, the show is at its best when it lets disagreement and uncertainty remain visible. It asks what is known. It asks what is being assumed. Then it asks who pays the price when a theory, treatment, or policy is wrong. The result is not polished institutional science communication. It is a working conversation about drug knowledge as it actually circulates through clinics, streets, books, studies, and recovery systems.
Made for: For listeners who follow psychopharmacology, addiction policy, mental health research, and contested medical claims. It especially suits people who like expert interviews that connect mechanisms to lived outcomes.
What sets it apart: The show joins technical drug discussion with uncomfortable policy and recovery questions, making pharmacology feel less abstract. Its best episodes let guests complicate the tidy version of medical news.
Join Dr. Carlos on “Pharmacology Insights,” your source for the latest research and news on pharmacology, medications, and street drugs. Each episode delves into cutting-edge discoveries, practical applications, and the evolving landscape of both legal and illicit substances. Gain a deeper understanding of how drugs work, their impacts on health, and the latest trends in medication and drug use. Tune in for expert analysis and insightful discussions that keep you informed on all things pharmacological.
Based on 6 episodes we listened to · September 2026
Guest interviews connect drug mechanisms and research disputes with the lived consequences of treatment, addiction and public policy.
Pharmacology News follows Dr. Carlos into the contested territory around medicines, mental health and illegal drugs, usually through extended guest interviews.
Ibogaine receptors meet housing policy; Dr. Carlos gives your curiosity a larger notebook.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
Housing first is weighed against overdose risk, isolation, and the hard edge of San Francisco's SRO reality.
Tom Wolfe's talk with Dr. Carlos keeps its focus on a blunt question: what does help look like when housing is part of the problem too? Wolfe makes a forceful case for permanent supportive housing, points to San Francisco SROs, and anchors the argument in the claim that 37…
A careful challenge to the serotonin story, built from trial details rather than slogans.
Pharmacology Daily takes on a familiar but still combustible question: what happens when Dr. Joanna Moncrief challenges the serotonin story around depression, with Dr. Carlos giving her room to make the case.
A wide, mechanism-first look at how vitamin D and sleep keep showing up together.
Dr. Gominak frames vitamin D as more than a nutrient score, linking it to sleep, light, and the way medicine overlooked what changed when people moved indoors.
Tom Wolfe grounds the conversation in lived experience with homelessness and addiction.
Tom Wolfe, founder of the Pacific Alliance for Prevention and Recovery, gives the episode its clearest throughline as it moves from the Tenderloin to heroin and fentanyl addiction, and to his six months of homelessness in San Francisco in 2018. Dr.
A clear introduction to why emotions may fit recurring survival situations.
Dr. Carlos speaks with Dr. Randolph Nessie about Good Reasons for Bad Feelings and the logic of evolutionary psychiatry, asking not why some people suffer but why natural selection has left emotions that can come at a cost.
Particle accelerators, compost piles and Queen's guitarist, all explained.
Steven Novella and a rotating panel dissect weekly science news and debunk pseudoscience claims.
APA's Kim Mills interviews psychology researchers on tipping, crying, and extremism.
Dr.
Dr.
Dr.
Wolfe says San Francisco had "37 people a month" dying of overdose inside SRO housing.
Dr.
Dr.
Pharmacology Daily pairs Dr.
["Pharmacology Daily centers on Tom Wolfe\u2019s account of oxycodone addiction, Tenderloin street buying, homelessness, and recovery policy.", "Dr.
Dr.